Effects of tissue plasminogen activator and dual antiplatelet therapy in acute ischemic stroke treatment

A comparative study of the effects of tissue plasminogen activator and dual antiplatelet therapy on improvement of the score of the National Institutes of Health Stroke Scale in acute ischemic stroke treatment

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017082117756N24

Enrollment

Registered

2017-09-10

Start date

2017-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic stroke. cerebrovascular (embolic) (ischemic) (thrombotic)

Interventions

Intervention 1: Intervention Group (tissue plasminogen activator ): The cases receive tissue plasminogen activator (Retavase®) 0.9 milligram per kilogram (maximum doses: 90 milligram) where 10 percent

Treatment - Drugs

Intervention Group (tissue plasminogen activator ): The cases receive tissue plasminogen activator (Retavase®) 0.9 milligram per kilogram (maximum doses: 90 milligram) where 10 percent of the total do

Control Group (dual antiplatelet therapy): The controls receive dual antiplatelet therapy by daily aspirin 80 milligram and clopidogrel 75 milligram for three months. After three months, the clopidogr

Eligibility

Sex/Gender

All

Age

No minimum to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Proved ischemic stroke; informed consent for participation; stroke symptoms initiated within 4.5 hours before admission; no brain hemorrhage on initial computerized tomography scan; clinical national institutes of health stroke scale between 4 and 18. Exclusion criteria: Age 80 years or above; brain hemorrhage in initial computerized tomography scan; history of stroke; history of diabetes mellitus; patients currently receiving oral anticoagulant treatment without considering the international normalized ratio; clinical national institutes of health stroke scale above 25; large ischemic changes of brain or involvement of more than one-third of middle cerebral artery supplying zone in the initial computerized tomography scan.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
National Institutes of Health Stroke Scale score. Timepoint: at the initial presentation, after 24 and 48 hours, and at discharge from hospital. Method of measurement: Physical examination.	—

Secondary

Measure	Time frame
Complications of tissue plasminogen activator treatment. Timepoint: after 24 and 48 hours from the initiation of treatment and at discharge from hospital. Method of measurement: brain computerized tomography scan.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Elham Zarei

Birjand University of Medical Sciences

dr.elizarei@yahoo.com+98 56 3222 5402

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026